Small-molecule inhibitors of BET family proteins have shown promise as antileukemic agents in some leukemia cell lines and primary leukemic cells harboring MLL fusions or NPMc+ mutations [6, 7, 14–17], although resistance has also been documented [16, 17]. Here, KMT2A is linked to leukemia.